Regulatory Decision-Making Meets the Real World

Friends publishes commentary in Science Translational Medicine and Whitepaper Report on patient-centered drug development. Links below:

AAAS' Science Translational Medicine

Friends Whitepaper - Enhancing Use of Patient-Centered Data in Regulatory Decision Making

 

19th Annual Cancer Leadership Awards Reception

Friends Honors Rep. Fred Upton, Rep. Diana DeGette, and President Marlene Malek as Dr. Francis Collins sings, "If Not Now, Tell Me When"

Read More

Ellen Sigal Op-Ed in The Hill on Updating FDA Structure

Ellen Sigal Calls for updated FDA structure for 21st Century science and patient needs

Read More

2014 Conference on Clinical Cancer Research

Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.

Read More

Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way possible.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Breakthrough Therapies In Action

The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.

Read More
View More

Recent and Upcoming Events

Breakthrough Designations

View More

Sacituzumab govitecan (IMMU-132) - (Immunomedics)

for the treatment of patients with triple-negative breast cancer (TNBC) following at least 2 treatments for metastatic disease

 

Venetoclax - (AbbVie/Roche)

for the treatment of patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy)